Patent ID: 7291343

Claim:
A composition comprising (i) an isolated polysaccharide E. faecalis antigen and (ii) an isolated polysaccharide E. faecium antigen, and (iii) a sterile, pharmaceutically-acceptable carrier therefore, wherein: said isolated polysaccharide E. faecalis antigen is different from said isolated polysaccharide E. faecium antigen, and said antigens are selected from the group consisting of: a polysaccharide E. faecalis antigen comprising 2-acetamido-2-deoxy-glucose, rhamnose, glucose, and 2-acetamido-2-deoxy-galactose in a 1:2:2:2 molar ratio as its major sugar groups and that specifically reacts with antibody to ATCC 20213; a polysaceharide E. faecalis antigen comprising a trisaccharide repeat that comprises a 6-deoxy sugar and that does not comprise sugars with N-acetyl or O-acetyl substituents, wherein the antigen further comprises acidic groups and specifically reacts with antibody to ATCC 20214; and a polysaccharide E. faecium antigen comprising 2-acetamido-2-deoxy-galactose and galactose as its major sugar components and that specifically reacts with antibody to ATCC 20215.